PHARMACEUTICAL COMPOSITION COMPRISING IU1-LINEAGE UBIQUITIN-SPECIFIC PROTEASE 14 INHIBITOR AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF PROTAC

Abstract

The present invention relates to a pharmaceutical composition for enhancing an anticancer effect and, more specifically, identifies that when administered in combination with PROTAC, a composition comprising an IU1-lineage compound, known to inhibit the deubiquitinase USP14, remarkably enhances the prophylactic or therapeutic effect of PROTAC on cancer. In addition, even when PROTAC is used at a lower dose than conventional doses, the utilization of the pharmaceutical composition of the present invention can effectively treat cancer, thus being free from the problems of toxicity and adverse effects. The pharmaceutical composition overcomes the applicative limitations and problems generated upon the use of PROTAC alone and thus can be widely used in the anticancer therapy field.